Literature search on point of care monitoring for INR and APTT

Point of care monitoring of anticoagulant (warfarin or acenocoumarol) therapy is usually done with a portable device on which a drop of capillary blood is added. The device will measure the coagulation time under certain conditions.

For example, in order to measure the INR, the device will contain a film of thromboplastin.

Medline search: ((point of care) or poc) and (inr or aptt)

1:  McGriff-Lee NJ, Csako G, Chen JT, Dang DK, Rosenfeld KG, Cannon RO, Macklin
LR, Wesley RA. 
 Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy.
Ann Pharmacother. 2005 Dec;39(12):1996-2002. Epub 2005 Nov 15. 

2:  Phillips EM, Buchan DA, Newman N, Rajan A, Zia S. 
 Low-molecular-weight heparin may alter point-of-care assay for international
normalized ratio.
Pharmacotherapy. 2005 Oct;25(10):1341-7. 

3:  Newall F, Monagle P, Johnston L. 
 Home INR monitoring of oral anticoagulant therapy in children using the
CoaguChektrade mark S point-of-care monitor and a robust education program.
Thromb Res. 2005 Sep 13; [Epub ahead of print] 

4:  Molitor B, Klingel R, Hafner G. 
 [Monitoring of the heparin therapy during acute haemodialysis]
Hamostaseologie. 2005 Aug;25(3):272-8; quiz 279-80. Review. German. 

5:  Indredavik B, Rohweder G, Lydersen S. 
 Frequency and effect of optimal anticoagulation before onset of ischaemic
stroke in patients with known atrial fibrillation.
J Intern Med. 2005 Aug;258(2):133-44. 

6:  Claes N, Buntinx F, Vijgen J, Arnout J, Vermylen J, Fieuws S, Van Loon H. 
 Quality assessment of oral anticoagulation in Belgium, as practiced by a group
of general practitioners.
Acta Cardiol. 2005 Jun;60(3):247-52. 

7:  van den Besselaar AM, Hoekstra MM. 
 Long-term stability and reproducibility of CoaguChek test strips.
Thromb Haemost. 2005 Jun;93(6):1189-92. 

8:  Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. 
 Anticoagulation monitoring part 2: Unfractionated heparin and
low-molecular-weight heparin.
Ann Pharmacother. 2005 Jul-Aug;39(7-8):1275-85. Epub 2005 Jun 14. Review. 

9:  Dorfman DM, Goonan EM, Boutilier MK, Jarolim P, Tanasijevica M, Goldhaber
SZ. 
 Point-of-care (POC) versus central laboratory instrumentation for monitoring
oral anticoagulation.
Vasc Med. 2005 Feb;10(1):23-7. 

10:  Doherty TM, Shavelle RM, French WJ. 
 Reproducibility and variability of activated clotting time measurements in the
cardiac catheterization laboratory.
Catheter Cardiovasc Interv. 2005 Jul;65(3):330-7. 

11:  Spinler SA, Nutescu EA, Smythe MA, Wittkowsky AK. 
 Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin
inhibitors.
Ann Pharmacother. 2005 Jun;39(6):1049-55. Epub 2005 Apr 26. 

12:  Sunderji R, Gin K, Shalansky K, Carter C, Chambers K, Davies C, Schwartz L,
Fung A. 
 Clinical impact of point-of-care vs laboratory measurement of anticoagulation.
Am J Clin Pathol. 2005 Feb;123(2):184-8. 

13:  Wittkowsky AK, Sekreta CM, Nutescu EA, Ansell J. 
 Barriers to patient self-testing of prothrombin time: national survey of
anticoagulation practitioners.
Pharmacotherapy. 2005 Feb;25(2):265-9. 

14:  Lata J, Husova L, Jurankova J, Senkyrik M, Dite P, Dastych M, Dastych M,
Kroupa R. 
 [Factors participating in development of bleeding varices in portal
hypertension. Part II: Possible impact of kidney damage and malnutrition,
mortality]
Vnitr Lek. 2004 Dec;50(12):901-6. Czech. 

15:  McBane RD 2nd, Felty CL, Hartgers ML, Chaudhry R, Beyer LK, Santrach PJ. 
 Importance of device evaluation for point-of-care prothrombin time
international normalized ratio testing programs.
Mayo Clin Proc. 2005 Feb;80(2):181-6. 

16:  Iqbal O, Tobu M, Aziz S, Gerdisch M, Da Valle M, Demir M, Hoppensteadt DA,
Ahmad S, Walenga JM, Fareed J. 
 Successful use of recombinant hirudin and its monitoring by ecarin clotting
time in patients with heparin-induced thrombocytopenia undergoing off-pump
coronary artery revascularization.
J Card Surg. 2005 Jan-Feb;20(1):42-51. 

17:  Gardiner C, Williams K, Mackie IJ, Machin SJ, Cohen H. 
 Patient self-testing is a reliable and acceptable alternative to laboratory INR
monitoring.
Br J Haematol. 2005 Jan;128(2):242-7. 

18:  Nutescu EA. 
 Point of care monitors for oral anticoagulant therapy.
Semin Thromb Hemost. 2004 Dec;30(6):697-702. Review. 

19:  Voller H, Dovifat C, Glatz J, Kortke H, Taborski U, Wegscheider K. 
 Self management of oral anticoagulation with the IN Ratio system: impact of a
structured teaching program on patient's knowledge of medical background and
procedures.
Eur J Cardiovasc Prev Rehabil. 2004 Oct;11(5):442-7. 

20:  Bakhtiari K, Meijers JC, de Jonge E, Levi M. 
 Prospective validation of the International Society of Thrombosis and
Haemostasis scoring system for disseminated intravascular coagulation.
Crit Care Med. 2004 Dec;32(12):2416-21. 

21:  Jackson SL, Peterson GM, House M, Bartlett T. 
 Point-of-care monitoring of anticoagulant therapy by rural community
pharmacists: description of successful outcomes.
Aust J Rural Health. 2004 Oct;12(5):197-200. 

22:  Weilbach C, Scheinichen D, Juttner B, Schurholz T, Piepenbrock S. 
 [Excessive blood loss after abdominal hysterectomy -- use of recombinant factor
VIIa]
Anasthesiol Intensivmed Notfallmed Schmerzther. 2004 Nov;39(11):672-5. German. 

23:  Murray ET, Fitzmaurice DA, McCahon D. 
 Point of care testing for INR monitoring: where are we now?
Br J Haematol. 2004 Nov;127(4):373-8. Review. 

24:  Ignjatovic V, Barnes C, Newall F, Hamilton S, Burgess J, Monagle P. 
 Point of care monitoring of oral anticoagulant therapy in children: comparison
of CoaguChek Plus and Thrombotest methods with venous international normalised
ratio.
Thromb Haemost. 2004 Oct;92(4):734-7. 

25:  Sunderji R, Gin K, Shalansky K, Carter C, Chambers K, Davies C, Schwartz L,
Fung A. 
 A randomized trial of patient self-managed versus physician-managed oral
anticoagulation.
Can J Cardiol. 2004 Sep;20(11):1117-23. 

26:  Colombet I, Bura-Riviere A, Chatila R, Chatellier G, Durieux P; PHRC-OAT
study group. 
 Personalized versus non-personalized computerized decision support system to
increase therapeutic quality control of oral anticoagulant therapy: an
alternating time series analysis.
BMC Health Serv Res. 2004 Sep 29;4(1):27. 

27:  Amruso NA. 
 Ability of clinical pharmacists in a community pharmacy setting to manage
anticoagulation therapy.
J Am Pharm Assoc (Wash DC). 2004 Jul-Aug;44(4):467-71. 

28:  Woods K, Douketis JD, Schnurr T, Kinnon K, Powers P, Crowther MA. 
 Patient preferences for capillary vs. venous INR determination in an
anticoagulation clinic: a randomized controlled trial.
Thromb Res. 2004;114(3):161-5. 

29:  Jonsson M, Hillarp A, Svensson P. 
 Comparison between CoaguChek S- and Owren-type prothrombin time assay for
monitoring anticoagulant therapy.
Thromb Res. 2004;114(2):83-9. 

30:  Gerasimou A, Oliaro E, Quaglia C, Canta M, Calachanis M, Morello M,
Mangiardi L. 
 When should asymptomatic patients with combined severe aortic stenosis and
aortic insufficiency undergo valve replacement? A clinical case.
Minerva Cardioangiol. 2004 Aug;52(4):339-44. English, Italian. 

31:  Jackson SL, Peterson GM, Vial JH, Jupe DM. 
 Improving the outcomes of anticoagulation: an evaluation of home follow-up of
warfarin initiation.
J Intern Med. 2004 Aug;256(2):137-44. 

32:  Gerdle B, Bjork J, Henriksson C, Bengtsson A. 
 Prevalence of current and chronic pain and their influences upon work and
healthcare-seeking: a population study.
J Rheumatol. 2004 Jul;31(7):1399-406. 

33:  Horstkotte D, Piper C. 
 Modern aspects of antithrombotic treatment: an introduction.
J Heart Valve Dis. 2004 May;13(3):314-8. Review. 

34:  Jacobson AK. 
 The North American experience with patient self-testing of the INR.
Semin Vasc Med. 2003 Aug;3(3):295-302. Review. 

35:  Tripodi A, Breukink-Engbers WG, van den Besselaar AM. 
 Oral anticoagulant monitoring by laboratory or near-patient testing: what a
clinician should be aware of.
Semin Vasc Med. 2003 Aug;3(3):243-54. Review. 

36:  Chaudhry R, Scheitel SM, Stroebel RJ, Santrach PJ, Dupras DM, Tangalos EG. 
 Patient satisfaction with point-of-care international normalized ratio testing
and counseling in a community internal medicine practice.
Manag Care Interface. 2004 Mar;17(3):44-6. 

37:  Tripodi A, Bressi C, Carpenedo M, Chantarangkul V, Clerici M, Mannucci PM. 
 Quality assurance program for whole blood prothrombin time-international
normalized ratio point-of-care monitors used for patient self-testing to control
oral anticoagulation.
Thromb Res. 2004;113(1):35-40. 

38:  Chavez JJ, Weatherall JS, Strevels SM, Liu F, Snider CC, Carroll RC. 
 Evaluation of a point-of-care coagulation analyzer on patients undergoing
cardiopulmonary bypass surgery.
J Clin Anesth. 2004 Feb;16(1):7-10. 

39:  Hambleton J. 
 Home monitoring of anticoagulation.
J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):39-42. Review. 

40:  York M, Agarwal A, Ezekowitz M. 
 Physicians' attitudes and the use of oral anticoagulants: surveying the present
and envisioning future.
J Thromb Thrombolysis. 2003 Aug-Oct;16(1-2):33-7. Review. 

41:  Vacas M, Lafuente PJ, Unanue I, Iriarte JA. 
 Comparative study of two portable systems for oral anticoagulant monitoring.
Hematol J. 2004;5(1):35-8. 

42:  Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C,
Jespersen J. 
 European concerted action on anticoagulation. Quality assessment of the
CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time
monitors.
Clin Chem. 2004 Mar;50(3):537-44. Epub 2004 Jan 6. 

43:  Morabito S, Guzzo I, Solazzo A, Muzi L, Luciani R, Pierucci A. 
 Continuous renal replacement therapies: anticoagulation in the critically ill
at high risk of bleeding.
J Nephrol. 2003 Jul-Aug;16(4):566-71. 

44:  Tobu M, Iqbal O, Messmore HL, Ma Q, Hoppensteadt DA, Fareed J. 
 Influence of different anticoagulant agents on fibrinopeptide a generation.
Clin Appl Thromb Hemost. 2003 Oct;9(4):273-92. 

45:  Kendall SA, Brolin-Magnusson K, Soren B, Gerdle B, Henriksson KG. 
 A pilot study of body awareness programs in the treatment of fibromyalgia
syndrome.
Arthritis Care Res. 2000 Oct;13(5):304-11. 

46:  Sander O, Reinhart K, Meier-Hellmann A. 
 Equivalence of hydroxyethyl starch HES 130/0. 4 and HES 200/0. 5 for
perioperative volume replacement in major gynaecological surgery.
Acta Anaesthesiol Scand. 2003 Oct;47(9):1151-8. 

47:  Poller L, Keown M, Chauhan N, Van Den Besselaar AM, Tripodi A, Shiach C,
Jespersen J; ECCA Steering Group Members. 
 European Concerted Action on Anticoagulation. Correction of displayed
international normalized ratio on two point-of-care test whole-blood prothrombin
time monitors (CoaguChek Mini and TAS PT-NC) by independent international
sensitivity index calibration.
Br J Haematol. 2003 Sep;122(6):944-9. 

48:  Lizotte A, Quessy I, Vanier MC, Martineau J, Caron S, Darveau M, Dube A,
Gilbert E, Blais N, Lalonde L. 
 Reliability, validity and ease of use of a portable point-of-care coagulation
device in a pharmacist-managed anticoagulation clinic.
J Thromb Thrombolysis. 2002 Dec;14(3):247-54. 

49:  Poller L, Keown M, Chauhan N, Van Den Besselaar AM, Tripodi A, Shiach C,
Jespersen J. 
 European Concerted Action on Anticoagulation (ECAA): an assessment of a method
for ISI calibration of two whole blood point-of-care PT monitor systems based on
lyophilized plasmas using whole blood equivalent PT.
J Thromb Haemost. 2003 Apr;1(4):766-72. 

50:  Sirithunyanont C, Bhuripanyo K, Kangkagate C, Winyarat W, Srichaya P,
Wangtip K. 
 Accuracy of international normalized ratio determined by portable venous-blood
coagulation monitor versus a central laboratory.
J Med Assoc Thai. 2003 May;86 Suppl 1:S67-75. 

51:  Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C,
Jespersen J. 
 Reliability of international normalised ratios from two point of care test
systems: comparison with conventional methods.
BMJ. 2003 Jul 5;327(7405):30. 

52:  Liepman CI, Koerber JM, Mattson JC, Westley SJ, Smythe MA. 
 Comparing methods of establishing the aPTT therapeutic range of heparin.
Ann Pharmacother. 2003 Jun;37(6):794-8. 

53:  Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E,
Wells PS. 
 Comparison of 10-mg and 5-mg warfarin initiation nomograms together with
low-molecular-weight heparin for outpatient treatment of acute venous
thromboembolism. A randomized, double-blind, controlled trial.
Ann Intern Med. 2003 May 6;138(9):714-9. 

54:  Tay MH, Tien SL, Chua TS, Sim LL, Koh TH. 
 An evaluation of point-of-care instrument for monitoring anticoagulation level
in adult cardiac patients.
Singapore Med J. 2002 Nov;43(11):557-62. 

55:  Calatzis A, Heesen M, Spannagl M. 
 [Point-of-care testing of hemostatic alterations in anaesthesia and intensive
care]
Anaesthesist. 2003 Mar;52(3):229-37. Review. German. 

56:  Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB,
Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ; PARAGON A Investigators. 
 An automated strategy for bedside aPTT determination and unfractionated heparin
infusion adjustment in acute coronary syndromes: insights from PARAGON A.
J Thromb Thrombolysis. 2002 Aug;14(1):33-42. 

57:  Johi RR, Cross MH, Hansbro SD. 
 Near-patient testing for coagulopathy after cardiac surgery.
Br J Anaesth. 2003 Apr;90(4):499-501. 

58:  Witt DM, Tillman DJ, Evans CM, Plotkin TV, Sadler MA. 
 Evaluation of the clinical and economic impact of a brand name-to-generic
warfarin sodium conversion program.
Pharmacotherapy. 2003 Mar;23(3):360-8. 

59:  De Waele JJ, Van Cauwenberghe S, Hoste E, Benoit D, Colardyn F. 
 The use of the activated clotting time for monitoring heparin therapy in
critically ill patients.
Intensive Care Med. 2003 Feb;29(2):325-8. Epub 2003 Jan 16. Erratum in:
Intensive Care Med. 2003 Apr;29(4):664. 

60:  Homoncik M, Pernerstorfer T, Reiter R, Knechtelsdorfer M, Quehenberger P,
Jilma B. 
 Point of care measurement of lepirudin and heparin anticoagulation during
systemic inflammation.
Thromb Res. 2002 Oct 1;108(1):91-5. 

61:  Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C,
Jespersen J. 
 European Concerted Action on Anticoagulation (ECAA). An assessment of
lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood
prothrombin time monitors.
J Clin Pathol. 2003 Feb;56(2):114-9. 

62:  Nowatzke WL, Landt M, Smith C, Wilhite T, Canter C, Luchtman-Jones L. 
 Whole blood international normalization ratio measurements in children using
near-patient monitors.
J Pediatr Hematol Oncol. 2003 Jan;25(1):33-7. 

63:  Jaryno S, Bennett K, Loder C, Zucker ML, Pan CM, LaDuca FM. 
 Validation of a new whole blood coagulation monitoring system.
J Extra Corpor Technol. 2002 Dec;34(4):271-5. 

64:  Poller L, Keown M, Chauhan N, Shiach C, van den Besselaar AM, Tripodi A,
Jespersen J; European Concerted Action on Anticoagulation. 
 European Concerted Action on Anticoagulation (ECAA): International Normalized
Ratio variability of CoaguChek and TAS point-of-care testing whole blood
prothrombin time monitors.
Thromb Haemost. 2002 Dec;88(6):992-5. 

65:  Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. 
 In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on
tests of coagulation.
Thromb Res. 2002 Sep 1;107(5):241-4. 

66:  Shermock KM, Bragg L, Connor JT, Fink J, Mazzoli G, Kottke-Marchant K. 
 Differences in warfarin dosing decisions based on international normalized
ratio measurements with two point-of-care testing devices and a reference
laboratory measurement.
Pharmacotherapy. 2002 Nov;22(11):1397-404. 

67:  Gill JM, Landis MK. 
 Benefits of a mobile, point-of-care anticoagulation therapy management program.
Jt Comm J Qual Improv. 2002 Nov;28(11):625-30. 

68:  Hafner G, Roser M, Nauck M. 
 Methods for the monitoring of direct thrombin inhibitors.
Semin Thromb Hemost. 2002 Oct;28(5):425-30. Review. 

69:  Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C,
Jespersen J; European Concerted Action on Anticoagulation (ECAA). 
 European Concerted Action on Anticoagulation (ECAA). Minimum number of centres
for reliable International Sensitivity Index calibration of CoaguChek and TAS
point-of-care whole blood monitors.
Thromb Res. 2002 Jul 15;107(1-2):61-6. 

70:  Shiach CR, Campbell B, Poller L, Keown M, Chauhan N. 
 Reliability of point-of-care prothrombin time testing in a community clinic: a
randomized crossover comparison with hospital laboratory testing.
Br J Haematol. 2002 Nov;119(2):370-5. 

71:  Searles B, Nasrallah F, Graham S, Tozer M. 
 Electronic data management for the Hemochron Jr. Signature coagulation
analyzer.
J Extra Corpor Technol. 2002 Sep;34(3):182-4. 

72:  Searles B, Nasrallah F, Graham S, Lajara RB. 
 Comparison of five point-of-care prothrombin and activated partial
thromboplastin time devices based on age of blood sample.
J Extra Corpor Technol. 2002 Sep;34(3):178-81. 

73:  Kagawa K. 
 [Prothrombin time and its standardization]
Rinsho Byori. 2002 Aug;50(8):779-85. Review. Japanese. 

74:  Iqbal O, Ahmad S, Lewis BE, Walenga JM, Rangel Y, Fareed J. 
 Monitoring of argatroban in ARG310 study: potential recommendations for its use
in interventional cardiology.
Clin Appl Thromb Hemost. 2002 Jul;8(3):217-24. 

75:  Holm T, Lassen JF, Husted SE, Heickendorff L. 
 The quality of routine oral anticoagulant therapy in a large geographical area.
A survey of 310,300 inhabitants.
Dan Med Bull. 2002 Aug;49(3):252-5. 

76:  Reiss RA, Haas CE, Griffis DL, Porter B, Tara MA. 
 Point-of-care versus laboratory monitoring of patients receiving different
anticoagulant therapies.
Pharmacotherapy. 2002 Jun;22(6):677-85. 

77:  Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C,
Jespersen J; European Concerted Action on Anticoagulation Steering Group
Members. 
 European Concerted Action on Anticoagulation--comparison of fresh plasma and
whole blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole
blood prothrombin time point-of-care monitors.
Thromb Haemost. 2002 May;87(5):859-66. 

78:  Ungerstedt JS, Kallner A, Blomback M. 
 Measurement of blood and plasma coagulation time using free oscillating
rheometry.
Scand J Clin Lab Invest. 2002;62(2):135-40. 

79:  Lundberg G, Gerdle B. 
 Tender point scores and their relations to signs of mobility, symptoms, and
disability in female home care personnel and the prevalence of fibromyalgia
syndrome.
J Rheumatol. 2002 Mar;29(3):603-13. 

80:  Rigelsky JM, Choe HM, Curtis DM, Brosnan MJ, Mitrovich S, Streetman DS. 
 Accuracy of the avosure PT pro system compared with a hospital laboratory
standard.
Ann Pharmacother. 2002 Mar;36(3):380-5. 

81:  Choi TS, Greilich PE, Shi C, Wilson JS, Keller A, Kroll MH. 
 Point-of-care testing for prothrombin time, but not activated partial
thromboplastin time, correlates with laboratory methods in patients receiving
aprotinin or epsilon-aminocaproic acid while undergoing cardiac surgery.
Am J Clin Pathol. 2002 Jan;117(1):74-8. 

82:  Schoen MD, DiDomenico RJ, Connor SE, Dischler JE, Bauman JL. 
 Impact of the cost of prescription drugs on clinical outcomes in indigent
patients with heart disease.
Pharmacotherapy. 2001 Dec;21(12):1455-63. 

83:  Ferring M, Reber G, de Moerloose P, Merlani P, Diby M, Ricou B. 
 Point of care and central laboratory determinations of the aPTT are not
interchangeable in surgical intensive care patients.
Can J Anaesth. 2001 Dec;48(11):1155-60. 

84:  Schroeder AP, Knudsen LL, Husted SE, Knudsen L, Ingerslev J. 
 Bedside coagulometry during intravenous heparin therapy after coronary
angioplasty.
J Thromb Thrombolysis. 2001 Oct;12(2):157-63. 

85:  van den Besselaar AM. 
 Accuracy, precision, and quality control for point-of-care testing of oral
anticoagulation.
J Thromb Thrombolysis. 2001 Sep;12(1):35-40. Review. 

86:  Kemme MJ, Faaij RA, Schoemaker RC, Kluft C, Meijer P, Cohen AF, Burggraaf
J. 
 Disagreement between bedside and laboratory activated partial thromboplastin
time and international normalized ratio for various novel anticoagulants.
Blood Coagul Fibrinolysis. 2001 Oct;12(7):583-91. 

87:  Fitzmaurice DA, Murray ET, Gee KM, Allan TF. 
 Does the Birmingham model of oral anticoagulation management in primary care
work outside trial conditions?
Br J Gen Pract. 2001 Oct;51(471):828-9. 

88:  Nowak G. 
 Clinical monitoring of hirudin and direct thrombin inhibitors.
Semin Thromb Hemost. 2001 Oct;27(5):537-41. Review. 

89:  Tseng LW, Hughes D, Giger U. 
 Evaluation of a point-of-care coagulation analyzer for measurement of
prothrombin time, activated partial thromboplastin time, and activated clotting
time in dogs.
Am J Vet Res. 2001 Sep;62(9):1455-60. 

90:  Hirsch J, Wendt T, Kuhly P, Schaffartzik W. 
 Point-of-care testing apparatus. Measurement of coagulation.
Anaesthesia. 2001 Aug;56(8):760-3. 

91:  Finck KM, Doetkott C, Miller DR. 
 Clinical impact of interlaboratory variation in international normalized ratio
determinations.
Am J Health Syst Pharm. 2001 Apr 15;58(8):684-8. 

92:  Oral Anticoagulation Monitoring Study Group. 
 Point-of-care prothrombin time measurement for professional and patient
self-testing use. A multicenter clinical experience. Oral Anticoagulation
Monitoring Study Group.
Am J Clin Pathol. 2001 Feb;115(2):288-96. 

93:  Smythe MA, Koerber JM, Westley SJ, Nowak SN, Begle RL, Balasubramaniam M,
Mattson JC. 
 Use of the activated partial thromboplastin time for heparin monitoring.
Am J Clin Pathol. 2001 Jan;115(1):148-55. 

94:  van den Besselaar AM, Meeuwisse-Braun J, Schaefer-van Mansfeld H, van Rijn
C, Witteveen E. 
 A comparison between capillary and venous blood international normalized ratio
determinations in a portable prothrombin time device.
Blood Coagul Fibrinolysis. 2000 Sep;11(6):559-62. 

95:  van den Besselaar AM, Moor AC. 
 Photodynamic treatment of pooled coumarin plasma for external quality
assessment of the prothrombin time.
J Clin Pathol. 2000 Jun;53(6):470-5. Erratum in: J Clin Pathol 2000
Aug;53(8):646. 

96:  von Kier S, Smith A. 
 Hemostatic product transfusions and adverse outcomes: focus on point-of-care
testing to reduce transfusion need.
J Cardiothorac Vasc Anesth. 2000 Jun;14(3 Suppl 1):15-21; discussion 37-8.
Review. No abstract available. 

97:  Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Burkard G, Heidinger
K. 
 [Background and evaluation plan of a study on self-management of
anticoagulation in patients with non-valvular atrial fibrillation (SMAAF Study)]
Z Kardiol. 2000 Apr;89(4):284-8. German. 

98:  Gosselin R, Owings JT, White RH, Hutchinson R, Branch J, Mahackian K,
Johnston M, Larkin EC. 
 A comparison of point-of-care instruments designed for monitoring oral
anticoagulation with standard laboratory methods.
Thromb Haemost. 2000 May;83(5):698-703. 

99:  Riley RS, Rowe D, Fisher LM. 
 Clinical utilization of the international normalized ratio (INR).
J Clin Lab Anal. 2000;14(3):101-14. Review. 

100:  Zimmerman CR. 
 The role of point-of-care anticoagulation monitoring in arterial and venous
thromboembolic disorders.
J Thromb Thrombolysis. 2000 Apr;9(3):187-98. Review. No abstract available. 

101:  Murray ET, Fitzmaurice DA, Allan TF, Hobbs FD. 
 A primary care evaluation of three near patient coagulometers.
J Clin Pathol. 1999 Nov;52(11):842-5. 

102:  Mamdani MM, Racine E, McCreadie S, Zimmerman C, O'Sullivan TL, Jensen G,
Ragatzki P, Stevenson JG. 
 Clinical and economic effectiveness of an inpatient anticoagulation service.
Pharmacotherapy. 1999 Sep;19(9):1064-74. 

103:  Hobbs FD, Fitzmaurice DA, Murray ET, Holder R, Rose PE, Roper JL. 
 Is the international normalised ratio (INR) reliable? A trial of comparative
measurements in hospital laboratory and primary care settings.
J Clin Pathol. 1999 Jul;52(7):494-7. 

104:  Becker RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ,
Jesse R, Hendel R, Ma Y, Hurley T, Hebert J. 
 A randomized, multicenter trial of weight-adjusted intravenous heparin dose
titration and point-of-care coagulation monitoring in hospitalized patients with
active thromboembolic disease. Antithrombotic Therapy Consortium Investigators.
Am Heart J. 1999 Jan;137(1):59-71. 

105:  Patel VB, Moliterno DJ. 
 Bedside activated partial thromboplastin time monitoring: just a matter of
time?
Am Heart J. 1999 Jan;137(1):8-11. No abstract available. 

106:  Boldt J, Walz G, Triem J, Suttner S, Kumle B. 
 Point-of-care (POC) measurement of coagulation after cardiac surgery.
Intensive Care Med. 1998 Nov;24(11):1187-93. 

107:  Lusher JM, Hillman-Wiseman C, Hurst D. 
 In vivo recovery with products of very high purity--assay discrepancies.
Haemophilia. 1998 Jul;4(4):641-5. 

108:  Koerner SD, Fuller RE. 
 Comparison of a portable capillary whole blood coagulation monitor and standard
laboratory methods for determining international normalized ratio.
Mil Med. 1998 Dec;163(12):820-5. 

109:  Zabel KM, Granger CB, Becker RC, Bovill EG, Hirsh J, Aylward PE, Topol EJ,
Califf RM. 
 Use of bedside activated partial thromboplastin time monitor to adjust heparin
dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I.
Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
Am Heart J. 1998 Nov;136(5):868-76. 

110:  Fitzmaurice DA, Hobbs FD, Murray ET. 
 Primary care anticoagulant clinic management using computerized decision
support and near patient International Normalized Ratio (INR) testing: routine
data from a practice nurse-led clinic.
Fam Pract. 1998 Apr;15(2):144-6. 

111:  Ereth MH, Nuttall GA, Santrach PJ, Klindworth JT, Oliver WC Jr, Schaff HV.

 The relation between the platelet-activated clotting test (HemoSTATUS) and
blood loss after cardiopulmonary bypass.
Anesthesiology. 1998 Apr;88(4):962-9. 

112:  Cachia PG, McGregor E, Adlakha S, Davey P, Goudie BM. 
 Accuracy and precision of the TAS analyser for near-patient INR testing by
non-pathology staff in the community.
J Clin Pathol. 1998 Jan;51(1):68-72. 

113:  Eiswirth G, Walch S, Bommer J. 
 New bedside test for monitoring anticoagulation during hemodialysis.
Artif Organs. 1998 Apr;22(4):346-8. 

114:  Solomon HM, Mullins RE, Lyden P, Thompson P, Hudoff S. 
 The diagnostic accuracy of bedside and laboratory coagulation: procedures used
to monitor the anticoagulation status of patients treated with heparin.
Am J Clin Pathol. 1998 Apr;109(4):371-8. 

115:  Henriksen RA, Dunham CK, Miller LD, Casey JT, Menke JB, Knupp CL, Usala
SJ. 
 Prothrombin Greenville, Arg517-->Gln, identified in an individual heterozygous
for dysprothrombinemia.
Blood. 1998 Mar 15;91(6):2026-31. 

116:  Kitchen S, Preston FE. 
 Monitoring oral anticoagulant treatment with the TAS near-patient test system:
comparison with conventional thromboplastins.
J Clin Pathol. 1997 Nov;50(11):951-6. 

117:  Ruzicka K, Kapiotis S, Quehenberger P, Handler S, Hornykewycz S, Michitsch
A, Huber K, Clemens D, Susan M, Pabinger I, Eichinger S, Jilma B, Speiser W. 
 Evaluation of bedside prothrombin time and activated partial thromboplastin
time measurement by coagulation analyzer CoaguCheck Plus in various clinical
settings.
Thromb Res. 1997 Sep 1;87(5):431-40. 

118:  Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci PM. 
 Determination of the International Sensitivity Index of a new near-patient
testing device to monitor oral anticoagulant therapy--overview of the assessment
of conformity to the calibration model.
Thromb Haemost. 1997 Aug;78(2):855-8. 

119:  Ereth MH, Nuttall GA, Klindworth JT, MacVeigh I, Santrach PJ, Orszulak TA,
Harmsen WS, Oliver WC Jr. 
 Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and
platelet dysfunction associated with cardiopulmonary bypass?
Anesth Analg. 1997 Aug;85(2):259-64. 

120:  Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. 
 Heparin detection by the activated coagulation time: a comparison of the
sensitivity of coagulation tests and heparin assays.
J Cardiothorac Vasc Anesth. 1997 Feb;11(1):24-8. 

121:  Leslie GD, Jacobs IG, Clarke GM. 
 Proximally delivered dilute heparin does not improve circuit life in continuous
venovenous haemodiafiltration.
Intensive Care Med. 1996 Nov;22(11):1261-4. 

122:  Paradiso-Hardy FL, Cheung B, Geerts WH. 
 Evaluation of an intravenous heparin nomogram in a coronary care unit.
Can J Cardiol. 1996 Sep;12(9):802-8. 

123:  Linder R, Grip L, Olason E, Blomback M. 
 Bedside heparin monitoring by activated partial thromboplastin time measured
with a dry reagent.
Clin Chem. 1996 Sep;42(9):1488-9. No abstract available. 

124:  Kessler CM, Bernstein Z, Ghesani S, Shamsipour Z, Frances C, Zucker ML,
LaDuca FM. 
 Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
Am J Hematol. 1996 Mar;51(3):181-5. 

125:  Burnakis TG. 
 Another perspective on monitoring anticoagulation therapy.
Ann Pharmacother. 1995 Oct;29(10):1045-6. No abstract available. 

126:  Preston FE. 
 Quality control and oral anticoagulation.
Thromb Haemost. 1995 Jul;74(1):515-20. 

127:  Werner M, Gallagher JV, Ballo MS, Karcher DS. 
 Effect of analytic uncertainty of conventional and point-of-care assays of
activated partial thromboplastin time on clinical decisions in heparin therapy.
Am J Clin Pathol. 1994 Aug;102(2):237-41. 

128:  Reiner JS, Coyne KS, Lundergan CF, Ross AM. 
 Bedside monitoring of heparin therapy: comparison of activated clotting time to
activated partial thromboplastin time.
Cathet Cardiovasc Diagn. 1994 May;32(1):49-52. 

129:  Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. 
 A method to determine the optimal intensity of oral anticoagulant therapy.
Thromb Haemost. 1993 Mar 1;69(3):236-9. 

130:  Bernardi M, Grazi GL, Colantoni A, Sica G, Mazziotti A, Trevisani F,
Gozzetti G, Gasbarrini G. 
 Prognostic indicators in patients with cirrhosis and hepatocellular carcinoma
undergoing surgical resection.
J Surg Oncol Suppl. 1993;3:67-9.